Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.

MC, Genovese; JS, Smolen; ME, Weinblatt; GR, Burmester; S, Meerwein; HS, Camp; L, Wang; AA, Othman; N, Khan; AL, Pangan; S, Jungerwirth

doi:10.1002/art.39808

Public

Efficacy and Safety of ABT-494, a Selective JAK-1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate.

Shared by NobleBlocks on Dec 1, 2016 • 12:00 AM UTC

Authors:

Genovese MC

Smolen JS

Weinblatt ME

Abstract

<h4>Objective</h4>To evaluate the efficacy and safety of ABT-494, a selective JAK-1 inhibitor, in patients with moderate-to-severe rheumatoid arthritis (RA) and an inadequate response to methotrexate (MTX).<h4>Methods</h4>Three hundred RA patients receiving stable doses of MTX were randomly assigned...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!